Abstract:Objective: To review the medical literature published in 2002 regarding menopausal hormone therapy and its impact on clinical practice. Methods: A literature search was performed using MEDLINE with the keywords of menopause, sex steroids, and hormone replacement therapy. Randomized clinical trials were reviewed. An evidence-based review is presented. Results: Menopausal hormone therapy has undergone radical change since the publication of the Women's Health Initiative randomized prospective trial of combined estrogen plus progestin therapy for disease prevention. After a mean of 5.2 years of follow-up, the E + P versus placebo trial of 16,608 women was stopped because the health risks of taking E + P exceeded the benefits. An increase in breast cancer risk, coupled with an adverse trend in overall risk-benefit ratio, reached the preset stopping boundaries. In addition, there was an increased risk of nonfatal myocardial infarction, stroke, and pulmonary embolism. The decreased risks seen for osteoporotic fracture and colorectal cancer were outweighed by the above risks. The FDA has required mandatory label changes for all hormone products based on these findings. The Women's Health Initiative found that treatment with estrogen plus progestin for up to 5 years is not beneficial overall. There is early harm for coronary heart disease, continuing harm for stroke and venous thromboembolism, and increasing harm for breast cancer. This risk-benefit profile is not consistent with a viable intervention for primary prevention of chronic diseases in postmenopausal women. Menopausal hormone therapy should be reserved for women with moderate to severe vasomotor symptoms. Conclusions: In the past 20 years, menopause has become a household word, with much better understanding of its consequences. The growing numbers of menopausal women and clinical trials have coincided to draw increasing attention to the perimenopausal and menopausal years. Better studies of older therapies and the expanded number of new choices today, with more in development and evaluation, have complicated provider and patient choices but greatly improved the potential for effective intervention.

The indications and development history of hormone replacement therapy for menopause

Combining traditional Chinese medicine and western medicine and psychological intervention in treatment of 110 cases with perimenopausal syndrome

The use and discontinuation of hormone replacement therapy in women in South China

Knowledge and Attitude Towards Menopause and Hormone Replacement Therapy in Chinese Women.

Update on hormone therapy for the management of postmenopausal women

Low-dose hormone therapy in postmenopausal women in China

Advantages and Disadvantages of Menopause Hormone Therapy

The treatment of menopausal symptoms by traditional Chinese medicine in Asian countries

Hormones, herbal preparations and nutriceuticals for a better life after the menopause: part I

[Hormone therapy in menopause. A current update]

Update on the Diagnosis and Treatment of Menopause Syndrome

The therapeutic choice of women menopause

Estrogen deficiency in the menopause and the role of hormone therapy: integrating the findings of basic science research with clinical trials

Efficacy and safety evaluation of standardized management of hormone therapy in menopausal women

Menopausal hormone therapy and coronary heart disease: the roller-coaster history

Perimenopausal and Postmenopausal Health

Advances in diagnosis and treatment of perimenopausal syndrome

Hormone therapy: evolving concepts

Investigation on Awareness of Perimenopausal Hormone Replacement Therapy

Safety and benefit considerations for menopausal hormone therapy

Research Progress of the Risk of Tumors of Menopausal Hormone Replacement Therapy